“…In addition, BCL11A is included in most CNVs reported as the 2p15‐p16.1 microdeletion syndrome (OMIM #612513), characterized by developmental delay, intellectual disability, hypotonia, poor verbal skills, craniofacial and skeletal features, digital anomalies, and fetal hemoglobin persistence (Basak et al, 2015; Funnell et al, 2015). When described, patients with 2p15p16 microdeletion encompassing BCL11A show delayed receptive and expressive language skills (Hancarova et al, 2013; Piccione et al, 2012; Rajcan‐Separovic et al, 2007), language delay (Balci, Sawyer, Davila, Humphreys, & Dyment, 2015; Felix, Petrin, Sanseverino, & Murray, 2010), language restricted to a few single words and signing (Florisson et al, 2013), or absence of language (Florisson et al, 2013; Hucthagowder et al, 2012). Apart from Peter, Matsushita, Oda, and Raskind, (2014), who described a 200 kb 2p15p16.1 deletion encompassing the entire BCL11A gene (plus 50 kb of non‐coding sequence but no other known coding or non‐coding gene) in a patient with mild intellectual disability, childhood apraxia of speech, dysarthria, and oral and motor dyspraxia, language anomalies have not been extensively studied in patients with mutations or microdeletions affecting BCL11A .…”